MKMiyuki Kawase

Miyuki Kawase

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Miyuki Kawase has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Establishment of a human coronavirus HKU1 infection evaluation system using apical-out airway organoids

    by Masatoshi Kakizaki, Satoko Sugimoto, Miyuki Kawase, Sakurako Norito, Hisao Okabe, Hayato Go, Koichi Hashimoto, Kazuya Shirato

    Human coronavirus HKU1 (HCoV-HKU1) is difficult to study because it does not propagate in standard cell lines. Consequently, research has relied on the air–liquid interface model, which is limited by long culture periods and the absence of cytopathic effects (CPEs). To address these challenges, we established an infection evaluation system using apical-out airway organoids (AOAOs). Derived from human bronchial epithelial cells, AOAOs supported efficient HCoV-HKU1 replication, and immunofluorescence revealed a preferential infection of ciliated cells. Notably, HCoV-HKU1 induced a distinct CPE characterized by organoid dissociation, enabling the quantification of viral titres via the TCID 50 assay. Applying this model to antiviral testing, the serine protease inhibitor nafamostat effectively inhibited viral infection and CPE, consistent with the known entry mechanism. Thus, AOAOs provide a rapid, scalable and reproducible platform for HCoV-HKU1 research, overcoming limitations of traditional systems. This approach enables reliable viral replication analysis, titre determination and drug evaluation and may accelerate research on difficult-to-culture respiratory viruses.

  • Open Access

    Temporal genetic changes in human bocavirus 1 in Fukushima, Japan, from 2018 to 2024

    by Tatsuya Shirai, Miyuki Kawase, Satoko Sugimoto, Masatoshi Kakizaki, Takashi Okura, Yohei Kume, Hisao Okabe, Sakurako Norito, Hiroko Sakuma, Shigeo Suzuki, et al.

    Introduction. Human bocavirus 1 (HBoV1) is a member of Bocaparvovirus primate1 and is associated with paediatric respiratory infections. Although genetic grouping has been described, it remains unclear whether temporal genetic changes occur among clinically circulating HBoV1 strains. Hypothesis/Gap Statement. HBoV1 shows limited genetic diversity, but temporal genetic changes may occur in circulating strains. Aim. To investigate whether temporal genetic changes are present in HBoV1 isolates collected in Fukushima, Japan, between 2018 and 2024. Methodology. Nasopharyngeal swabs were collected from paediatric inpatients with acute respiratory infections. Thirty-two HBoV1 isolates were obtained using air–liquid interface cultures of human bronchial/tracheal epithelial cells. Nearly complete genomes were sequenced by next-generation sequencing and analysed together with additional reference sequences (total n =100, including outgroups) using phylogenetic and time-scaled methods. Results. Phylogenetic analyses classified the 32 Fukushima isolates into Group 1 ( n =12) and Group 2 ( n =20). Group 2 predominated in 2018, Group 1 from 2019 to 2021 and Group 2 again from 2022 to 2024, indicating temporal shifts in circulating strains. The average number of nucleotide differences among HBoV1 genomes was 13.9 (maximum 55), with Groups 1 and 2 diverging around 2004–2005. Divergence was concentrated in the VP genes, and synonymous substitutions within VP genes overlapped the ORFx reading frame, leading to distinct amino acid differences in ORFx. Conclusion. Clinically circulating HBoV1 undergoes temporal genetic change, with group differentiation determined primarily by VP genes and uniquely by ORFx at the amino acid level. These findings suggest a potential biological role for ORFx in the HBoV1 life cycle. Understanding these temporal genetic shifts is important for enhancing the accuracy of molecular surveillance tools, particularly for distinguishing genetically diverse HBoV1 strains.

  • Open Access

    Changes in ORF4 of HCoV-229E under different culture conditions

    by Yuki Kitai, Shohei Kojima, Aikeda Aishajiang, Miyuki Kawase, Oshi Watanabe, Haruka Yabukami, Rina Hashimoto, Yukiko Akahori, Hiroshi Katoh, Kazuo Takayama, et al.

    The genome of human coronavirus 229E (HCoV-229E), a causative agent of human respiratory infections, encodes a unique accessory gene, ORF4. Analysis of laboratory strains and clinical specimens has suggested that HCoV-229E acquires truncating mutations in ORF4 under standard laboratory culture conditions. This study confirmed that HCoV-229E from patients with acute respiratory infections harboured a full-length ORF4 (219 amino acids). In contrast, virus stocks derived from the same patients and passaged in conventional cultured cells [LLC-MK2, human embryonic fibroblast (HEF); HEF, HeLa] exhibited truncated ORF4 of various lengths, such as 168, 143 and 16 amino acids. However, when these virus stocks were propagated in human bronchial/tracheal epithelial cells (HBTECs) cultured at the air–liquid interface (ALI), the full-length ORF4 was selected and stably maintained throughout a prolonged observation period. These findings highlight the importance of ORF4 in patients and under physiologically relevant conditions, and the HBTEC-ALI culture system is valuable for analyzing the native properties of HCoV-229E with an intact full-length ORF4.


  • Open Access

    Practical Validation of United States Centers for Disease Control and Prevention Assays for the Detection of Human Respiratory Syncytial Virus in Pediatric Inpatients in Japan

    by Reiko Suwa, Yohei Kume, Miyuki Kawase, Mina Chishiki, Takashi Ono, Sakurako Norito, Ko Sato, Michiko Okamoto, Satoru Kumaki, Yukio Nagai, et al.

    The World Health Organization initiated a global surveillance system for respiratory syncytial virus (RSV) in 2015, and the pilot surveillance is ongoing. The real-time RT-PCR RSV assays (Pan-RSV and duplex assays) developed by the United States Centers for Disease Control and Prevention are applied as the standard assays. To introduce these as standard assays in Japan, their practicality was evaluated using 2261 specimens obtained from pediatric inpatients in Japan, which were collected from 2018 to 2021. Although the Pan-RSV and duplex assays had similar analytical sensitivities, they yielded 630 (27.9%) and 786 (34.8%) RSV-positive specimens, respectively (p < 0.001). Although sequencing analysis showed mismatches in the reverse primer used in the Pan-RSV assay, these mismatches did not affect its analytical sensitivity. The analysis of read numbers of RSV isolates from air–liquid interface culture of human bronchial/tracheal epithelial cells showed that the duplex assay had a greater number of reads than did the Pan-RSV assay. Therefore, the duplex assay has superior detection performance compared with the Pan-RSV assay, but the two assays have similar analytical sensitivities.